関連レポート

抗がん剤市場：2031年予測

出版元：Transparency Market Research  出版元について

発行年：2024年2月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 182ページになります。

商品コード：TMR232

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

腫瘍溶解性ウイルス免疫療法の世界市場規模は2022年で1億1020万ドル、2031年に5億7220万ドル、市場の平均年成長率は21.1%にて増加する見込みです。

当レポートでは、腫瘍溶解性ウイルス免疫療法の市場予測-2031年、各種セグメント別市場分析(タイプ別、投与経路別、国地域別、等)、パイプライン分析、主要製品/ブランド分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。


【レポート構成概要】
■腫瘍溶解性ウイルス免疫療法の世界市場予測2017-2031年
・市場規模(US$)

■タイプ別、市場-2024年
・単純ヘルペスウイルス
・ワクシニアウイルス
・アデノウイルス
・レオウイルス
・その他
※(市場規模US$)　

■投与経路別、市場-2031年
・腫瘍内
・静脈内
※(市場規模US$)　

■用途別、市場-2031年
・悪性黒色腫
・非小細胞肺がん（NSCLC）
・膵臓がん
・乳がん
・その他
※(市場規模US$)

■主要国地域別市場-2031年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
南米
・ブラジル、アルゼンチン
・その他南米
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析
市場ダイナミクス
パイプライン分析
主要製品/ブランド分析
主要な合併、買収

■腫瘍溶解性ウイルス免疫療法の主要企業プロフィール動向
Merck & Co., Inc. (Viralytics Limited)
Amgen Inc.
Shanghai Sunway Biotech Co., Ltd.
TILT Biotherapeutics
Oncorus, Inc.
Replimune Group, Inc.
Oncolys Biopharma, Inc.
Sorrento Therapeutics, Inc.
Oncolytics Biotech, Inc.
SillaJen, Inc.

（全182頁）

Table of Contents (英文詳細目次）

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Oncolytic Virus Immunotherapy Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, 2017-2031

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017-2031
6.3.1. Herpes Simplex Virus
6.3.2. Vaccinia Virus
6.3.3. Adenovirus
6.3.4. Reovirus
6.3.5. Others
6.4. Market Attractiveness Analysis, by Type

7. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017-2031
7.3.1. Intratumoral
7.3.2. Intravenous
7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2017-2031
8.3.1. Melanoma
8.3.2. Non-small Cell Lung Cancer (NSCLC)
8.3.3. Pancreatic Cancer
8.3.4. Breast Cancer
8.3.5. Others
8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Oncolytic Virus Immunotherapy Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Type, 2017-2031
10.3.1. Herpes Simplex Virus
10.3.2. Vaccinia Virus
10.3.3. Adenovirus
10.3.4. Reovirus
10.3.5. Others
10.4. Market Value Forecast, by Route of Administration, 2017-2031
10.4.1. Intratumoral
10.4.2. Intravenous
10.5. Market Value Forecast, by Application, 2017-2031
10.5.1. Melanoma
10.5.2. Non-small Cell Lung Cancer (NSCLC)
10.5.3. Pancreatic Cancer
10.5.4. Breast Cancer
10.5.5. Others
10.6. Market Value Forecast, by Country, 2017-2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Type
10.7.2. By Route of Administration
10.7.3. By Application
10.7.4. By Country

11. Europe Oncolytic Virus Immunotherapy Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Type, 2017-2031
11.3.1. Herpes Simplex Virus
11.3.2. Vaccinia Virus
11.3.3. Adenovirus
11.3.4. Reovirus
11.3.5. Others
11.4. Market Value Forecast, by Route of Administration, 2017-2031
11.4.1. Intratumoral
11.4.2. Intravenous
11.5. Market Value Forecast, by Application, 2017-2031
11.5.1. Melanoma
11.5.2. Non-small Cell Lung Cancer (NSCLC)
11.5.3. Pancreatic Cancer
11.5.4. Breast Cancer
11.5.5. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Route of Administration
11.7.3. By Application
11.7.4. By Country/Sub-region

12. Asia Pacific Oncolytic Virus Immunotherapy Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Type, 2017-2031
12.3.1. Herpes Simplex Virus
12.3.2. Vaccinia Virus
12.3.3. Adenovirus
12.3.4. Reovirus
12.3.5. Others
12.4. Market Value Forecast, by Route of Administration, 2017-2031
12.4.1. Intratumoral
12.4.2. Intravenous
12.5. Market Value Forecast, by Application, 2017-2031
12.5.1. Melanoma
12.5.2. Non-small Cell Lung Cancer (NSCLC)
12.5.3. Pancreatic Cancer
12.5.4. Breast Cancer
12.5.5. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Route of Administration
12.7.3. By Application
12.7.4. By Country/Sub-region

13. Latin America Oncolytic Virus Immunotherapy Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Type, 2017-2031
13.3.1. Herpes Simplex Virus
13.3.2. Vaccinia Virus
13.3.3. Adenovirus
13.3.4. Reovirus
13.3.5. Others
13.4. Market Value Forecast, by Route of Administration, 2017-2031
13.4.1. Intratumoral
13.4.2. Intravenous
13.5. Market Value Forecast, by Application, 2017-2031
13.5.1. Melanoma
13.5.2. Non-small Cell Lung Cancer (NSCLC)
13.5.3. Pancreatic Cancer
13.5.4. Breast Cancer
13.5.5. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Route of Administration
13.7.3. By Application
13.7.4. By Country/Sub-region

14. Middle East & Africa Oncolytic Virus Immunotherapy Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Type, 2017-2031
14.3.1. Herpes Simplex Virus
14.3.2. Vaccinia Virus
14.3.3. Adenovirus
14.3.4. Reovirus
14.3.5. Others
14.4. Market Value Forecast, by Route of Administration, 2017-2031
14.4.1. Intratumoral
14.4.2. Intravenous
14.5. Market Value Forecast, by Application, 2017-2031
14.5.1. Melanoma
14.5.2. Non-small Cell Lung Cancer (NSCLC)
14.5.3. Pancreatic Cancer
14.5.4. Breast Cancer
14.5.5. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Route of Administration
14.7.3. By Application
14.7.4. By Country/Sub-region

15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Amgen Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Merck & Co., Inc. (Viralytics Limited)
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Shanghai Sunway Biotech Co., Ltd.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. TILT Biotherapeutics
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Oncorus, Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Replimune Group, Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Oncolys Biopharma, Inc.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Sorrento Therapeutics, Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Oncolytics Biotech, Inc.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. SillaJen, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview

List of Tables

Table 01: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031

Table 02: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 03: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031

Table 04: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Region, 2017-2031

Table 05: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2017-2031

Table 06: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031

Table 07: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 08: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031

Table 09: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 10: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031

Table 11: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 12: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031

Table 13: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 14: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031

Table 15: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 16: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031

Table 17: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 18: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031

Table 19: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 20: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031

Table 21: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 22: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031

Table 23: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 24: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031

List of Figures

Figure 01: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) and Distribution (%), by Region, 2022-2031

Figure 02: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Type, 2022

Figure 03: Global Oncolytic Virus Immunotherapy Market Value Share, by Type, 2022

Figure 04: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Route of Administration, 2022

Figure 05: Global Oncolytic Virus Immunotherapy Market Value Share, by Route of Administration, 2022

Figure 06: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Application, 2022

Figure 07: Global Oncolytic Virus Immunotherapy Market Value Share, by Application, 2022

Figure 08: Global Oncolytic Virus Immunotherapy Market Value Share, by Region, 2022

Figure 09: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, 2023-2031

Figure 10: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031

Figure 11: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031

Figure 12: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031

Figure 13: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031

Figure 14: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031

Figure 15: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2022-2031

Figure 16: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Region, 2022-2031

Figure 17: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Region, 2022-2031

Figure 18: North America Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

Figure 19: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country, 2023-2031

Figure 20: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country, 2022-2031

Figure 21: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031

Figure 22: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031

Figure 23: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031

Figure 24: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031

Figure 25: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031

Figure 26: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031

Figure 27: Europe Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

Figure 28: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 29: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031

Figure 30: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031

Figure 31: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031

Figure 32: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031

Figure 33: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031

Figure 34: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031

Figure 35: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031

Figure 36: Asia Pacific Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

Figure 37: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 38: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031

Figure 39: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031

Figure 40: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031

Figure 41: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031

Figure 42: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031

Figure 43: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031

Figure 44: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031

Figure 45: Latin America Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

Figure 46: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 47: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031

Figure 48: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031

Figure 49: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031

Figure 50: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031

Figure 51: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031

Figure 52: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031

Figure 53: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031

Figure 54: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031

Figure 55: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 56: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031

Figure 57: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031

Figure 58: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031

Figure 59: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031

Figure 60: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031

Figure 61: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031

Figure 62: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031

△ 一番上に戻る